ong-Term Follow-Up of Patients who have received an Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell Therapy (TX200-TR101) in a prior clinical study.

• Conditions: Allograft rejection; Renal transplant rejection; 10027665; 10029149

• Registration Number: NL-OMON56013
• Lead Sponsor: Sangamo Therapeutics France SAS

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 9 April 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 8

Inclusion Criteria

1. Subjects who enrolled in the Phase I/IIa study TX200-KT02, received a
transplanted kidney and have either completed or withdrawn from that study.
2. Willing and able to provide written informed consent (IC) in accordance with
local regulations and governing Independent Ethics Committee
(IEC)/Institutional Review Board (IRB) requirements prior to any procedure or
evaluation performed specifically for the sole purpose of the study.

Exclusion Criteria

1. Subjects/persons committed to an institution following an administrative or
judicial order.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified